Fate Therapeutics secured FDA IND clearance for FT-839, its next-generation off-the-shelf CAR T-cell candidate targeting CD19 and CD38 for autoimmune diseases. The company positioned FT-839 as part of its broader effort to scale repeatable cell therapy manufacturing and broaden clinical reach beyond oncology. With IND-enabling work complete enough for regulatory initiation, the practical milestone is the start of clinical planning under U.S. oversight—often a key gating item for fundraising and partnership discussions in cell therapy. Industry watchers will now focus on dosing approach, safety monitoring strategy, and the selection of autoimmune indications where target biology supports benefit-risk.